Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,010,000 shares, a growth of 13.5% from the May 31st total of 889,500 shares. Based on an average daily volume of 173,900 shares, the short-interest ratio is currently 5.8 days. Currently, 2.9% of the shares of the stock are short sold.

Athira Pharma Trading Up 0.4 %

• These biotechs targeting multiple neurodegenerative diseases

ATHA stock opened at $2.65 on Monday. The stock has a market cap of $101.57 million, a PE ratio of -0.87 and a beta of 2.91. Athira Pharma has a 12 month low of $1.33 and a 12 month high of $4.30. The company has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.72.

Athira Pharma (NASDAQ:ATHA - Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.11. Sell-side analysts forecast that Athira Pharma will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Athira Pharma news, Director Kelly A. Romano acquired 27,400 shares of the company's stock in a transaction on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the purchase, the director now directly owns 80,715 shares of the company's stock, valued at approximately $195,330.30. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Athira Pharma news, Director Kelly A. Romano purchased 27,400 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average price of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at $195,330.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Romano acquired 15,000 shares of Athira Pharma stock in a transaction on Friday, June 21st. The shares were bought at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the director now directly owns 53,315 shares of the company's stock, valued at $120,491.90. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by company insiders.

Institutional Trading of Athira Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. increased its stake in Athira Pharma by 84.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company's stock worth $1,363,000 after buying an additional 227,278 shares during the period. Acadian Asset Management LLC increased its position in shares of Athira Pharma by 281.5% during the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company's stock worth $1,505,000 after acquiring an additional 405,793 shares during the period. Mirador Capital Partners LP bought a new stake in shares of Athira Pharma during the first quarter valued at approximately $57,000. Perceptive Advisors LLC boosted its holdings in shares of Athira Pharma by 12.6% in the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company's stock valued at $13,129,000 after purchasing an additional 605,686 shares during the period. Finally, Forefront Analytics LLC grew its stake in Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company's stock worth $72,000 after purchasing an additional 8,955 shares in the last quarter. Hedge funds and other institutional investors own 57.12% of the company's stock.

Analyst Ratings Changes

Separately, JMP Securities restated a "market outperform" rating and issued a $19.00 price target on shares of Athira Pharma in a research report on Thursday, June 20th.

Check Out Our Latest Analysis on ATHA

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.

Featured Stories

• Five stocks we like better than Athira Pharma
• Golden Cross Stocks: Pattern, Examples and Charts
• Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
• How to Evaluate a Stock Before Buying
• What's Behind Walgreens Stock Plunge: What Investors Can Do Next
• What is MarketRank™? How to Use it
• MarketBeat Week in Review – 6/24 - 6/28

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Young billionaire opens the door for millions of Americans (From Porter & Company) (Ad)

Should you invest $1,000 in Athira Pharma right now?

Before you consider Athira Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Athira Pharma wasn't on the list.

While Athira Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here